Antibiotic monensin synergizes with EGFR inhibitors and oxaliplatin to suppress the proliferation of human ovarian cancer cells

[1]  T. He,et al.  The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways. , 2015, Current cancer drug targets.

[2]  Yinglin Xia,et al.  TqPCR: A Touchdown qPCR Assay with Significantly Improved Detection Sensitivity and Amplification Efficiency of SYBR Green qPCR , 2015, PloS one.

[3]  Gordon B Mills,et al.  Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours , 2015, Nature Communications.

[4]  T. He,et al.  Reversibly Immortalized Mouse Articular Chondrocytes Acquire Long-Term Proliferative Capability While Retaining Chondrogenic Phenotype , 2015, Cell transplantation.

[5]  T. He,et al.  Sustained high level transgene expression in mammalian cells mediated by the optimized piggyBac transposon system , 2015, Genes & diseases.

[6]  Jing Wang,et al.  Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance , 2014, Genes & diseases.

[7]  T. He,et al.  A Simplified and Versatile System for the Simultaneous Expression of Multiple siRNAs in Mammalian Cells Using Gibson DNA Assembly , 2014, PloS one.

[8]  S. Johnson-Obaseki,et al.  Monensin Inhibits Epidermal Growth Factor Receptor Trafficking and Activation: Synergistic Cytotoxicity in Combination with EGFR Inhibitors , 2014, Molecular Cancer Therapeutics.

[9]  T. He,et al.  The piggyBac Transposon-Mediated Expression of SV40 T Antigen Efficiently Immortalizes Mouse Embryonic Fibroblasts (MEFs) , 2014, PloS one.

[10]  X. Chen,et al.  Overexpression of Ad5 precursor terminal protein accelerates recombinant adenovirus packaging and amplification in HEK-293 packaging cells , 2014, Gene Therapy.

[11]  T. He,et al.  Characterization of Constitutive Promoters for piggyBac Transposon-Mediated Stable Transgene Expression in Mesenchymal Stem Cells (MSCs) , 2014, PloS one.

[12]  T. He,et al.  Adenovirus-Mediated Efficient Gene Transfer into Cultured Three-Dimensional Organoids , 2014, PloS one.

[13]  T. He,et al.  Adenovirus-Mediated Gene Transfer in Mesenchymal Stem Cells Can Be Significantly Enhanced by the Cationic Polymer Polybrene , 2014, PloS one.

[14]  J. Engelman,et al.  ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. , 2014, Cancer cell.

[15]  T. He,et al.  Targeting BMP9-promoted human osteosarcoma growth by inactivation of notch signaling. , 2014, Current cancer drug targets.

[16]  V. Kríz,et al.  Monensin Inhibits Canonical Wnt Signaling in Human Colorectal Cancer Cells and Suppresses Tumor Growth in Multiple Intestinal Neoplasia Mice , 2014, Molecular Cancer Therapeutics.

[17]  T. He,et al.  Crosstalk between Wnt/β-Catenin and Estrogen Receptor Signaling Synergistically Promotes Osteogenic Differentiation of Mesenchymal Progenitor Cells , 2013, PloS one.

[18]  Donald J Buchsbaum,et al.  The Wnt/β-catenin pathway in ovarian cancer: a review. , 2013, Gynecologic oncology.

[19]  T. He,et al.  Destabilization of Heterologous Proteins Mediated by the GSK3β Phosphorylation Domain of the β-Catenin Protein , 2013, Cellular Physiology and Biochemistry.

[20]  T. He,et al.  Noggin resistance contributes to the potent osteogenic capability of BMP9 in mesenchymal stem cells , 2013, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[21]  T. He,et al.  The E-F Hand Calcium-Binding Protein S100A4 Regulates the Proliferation, Survival and Differentiation Potential of Human Osteosarcoma Cells , 2013, Cellular Physiology and Biochemistry.

[22]  Sahdeo Prasad,et al.  Cancer drug discovery by repurposing: teaching new tricks to old dogs. , 2013, Trends in pharmacological sciences.

[23]  T. He,et al.  IGFBP5 domains exert distinct inhibitory effects on the tumorigenicity and metastasis of human osteosarcoma. , 2013, Cancer letters.

[24]  T. He,et al.  Cross-talk between EGF and BMP9 signalling pathways regulates the osteogenic differentiation of mesenchymal stem cells , 2013, Journal of cellular and molecular medicine.

[25]  Seo Yun Kim,et al.  Autophagy Inhibition with Monensin Enhances Cell Cycle Arrest and Apoptosis Induced by mTOR or Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cells , 2013, Tuberculosis and respiratory diseases.

[26]  T. He,et al.  Establishment and Characterization of the Reversibly Immortalized Mouse Fetal Heart Progenitors , 2013, International journal of medical sciences.

[27]  T. He,et al.  Ginseng saponin metabolite 20(S)-protopanaxadiol inhibits tumor growth by targeting multiple cancer signaling pathways , 2013, Oncology reports.

[28]  E. Oliva,et al.  Precursors and pathogenesis of ovarian carcinoma , 2013, Pathology.

[29]  J. Ledermann,et al.  Optimal first-line treatment in ovarian cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  B. Faircloth,et al.  Primer3—new capabilities and interfaces , 2012, Nucleic acids research.

[31]  M. Pollak.  The insulin and insulin-like growth factor receptor family in neoplasia: an update , 2012, Nature Reviews Cancer.

[32]  J. Qin,et al.  Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma , 2011, Oncogene.

[33]  W. McCluggage,et al.  Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. , 2011, Pathology.

[34]  P. Ghosh,et al.  Enhanced killing of human epidermoid carcinoma (KB) cells by treatment with ricin encapsulated into sterically stabilized liposomes in combination with monensin , 2011, Drug delivery.

[35]  T. He,et al.  Tetrandrine Inhibits Wnt/β-Catenin Signaling and Suppresses Tumor Growth of Human Colorectal Cancer , 2011, Molecular Pharmacology.

[36]  T. He,et al.  Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/ß-catenin signaling. , 2011, International journal of oncology.

[37]  O. Kallioniemi,et al.  Monensin Is a Potent Inducer of Oxidative Stress and Inhibitor of Androgen Signaling Leading to Apoptosis in Prostate Cancer Cells , 2010, Molecular Cancer Therapeutics.

[38]  T. He,et al.  Synergistic Antitumor Effect of the Activated PPARγ and Retinoid Receptors on Human Osteosarcoma , 2010, Clinical Cancer Research.

[39]  Ie-Ming Shih,et al.  The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.

[40]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[41]  Byung Min Chung,et al.  Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src@ , 2009, BMC Cell Biology.

[42]  T. He,et al.  BMP‐9‐induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/β‐catenin signalling , 2009, Journal of cellular and molecular medicine.

[43]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[44]  T. He,et al.  A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. , 2009, Stem cells and development.

[45]  T. He,et al.  Establishment and characterization of a new highly metastatic human osteosarcoma cell line , 2009, Clinical & Experimental Metastasis.

[46]  A. Montag,et al.  Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects , 2008, Laboratory Investigation.

[47]  K. Kinzler,et al.  A protocol for rapid generation of recombinant adenoviruses using the AdEasy system , 2007, Nature Protocols.

[48]  C. Heizmann,et al.  Increased expression of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma. , 2005, Cancer letters.

[49]  A. Godwin,et al.  Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study , 2005, Clinical Cancer Research.

[50]  L. B. Rocha,et al.  Mitochondrial damage as an early event of monensin-induced cell injury in cultured fibroblasts L929. , 2005, Journal of veterinary medicine. A, Physiology, pathology, clinical medicine.

[51]  J. Szatkowski,et al.  Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery , 2004, Gene Therapy.

[52]  R. Edwards,et al.  Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study , 2004, International Journal of Gynecologic Cancer.

[53]  B. Kim,et al.  Monensin-mediated growth inhibition in NCI-H929 myeloma cells via cell cycle arrest and apoptosis. , 2003, International journal of oncology.

[54]  Mandip Singh,et al.  Effect of monensin liposomes on the cytotoxicity of anti‐My9‐bR immunotoxin , 2003, The Journal of pharmacy and pharmacology.

[55]  Joon-Oh Park,et al.  Monensin inhibits the growth of renal cell carcinoma cells via cell cycle arrest or apoptosis. , 2003, International journal of oncology.

[56]  B. Kim,et al.  Monensin-mediated growth inhibition of SNU-C1 colon cancer cells via cell cycle arrest and apoptosis. , 2003, International journal of oncology.

[57]  A. Montag,et al.  Cytoplasmic and/or nuclear accumulation of the β‐catenin protein is a frequent event in human osteosarcoma , 2002, International journal of cancer.

[58]  Y. Im,et al.  Monensin‐mediated growth inhibition in human lymphoma cells through cell cycle arrest and apoptosis , 2002, British journal of haematology.

[59]  Keunchil Park,et al.  Monensin‐mediated growth inhibition in acute myelogenous leukemia cells via cell cycle arrest and apoptosis , 2002, International journal of cancer.

[60]  A. Montag,et al.  Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[61]  M. Singh,et al.  Stealth monensin liposomes as a potentiator of adriamycin in cancer treatment. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[62]  M. Brunori,et al.  The effect of monensin and chloroquine on the endocytosis and toxicity of chimeric toxins , 1998, Cellular and Molecular Life Sciences CMLS.

[63]  L. Recht,et al.  Potentiation of antitumor immunotoxins by liposomal monensin. , 1993, Journal of the National Cancer Institute.

[64]  R. Chignola,et al.  Blocking effect of human serum but not of cerebrospinal fluid on ricin A chain immunotoxin potentiation by monensin or carrier protein-monensin conjugates. , 1992, Cancer research.

[65]  R. Liteplo.  Transformed rodent cells exhibit increased resistance to the carboxylic ionophores monensin and nigericin. , 1991, Biochemical and biophysical research communications.

[66]  Pressman Bc.  Ionophorous antibiotics as models for biological transport. , 1968 .

[67]  T. He,et al.  Canonical Wnt signaling acts synergistically on BMP9-induced osteo/odontoblastic differentiation of stem cells of dental apical papilla (SCAPs). , 2015, Biomaterials.

[68]  Y. Quan,et al.  Medical genetic inspirations for anticancer drug repurposing. , 2014, Trends in pharmacological sciences.

[69]  Junhui Zhanga,et al.  Hand Calcium-Binding Protein S 100 A 4 Regulates the Proliferation , Survival and Differentiation Potential of Human Osteosarcoma Cells , 2013 .

[70]  A. Montag,et al.  An Orthotopic Model of Human Osteosarcoma Growth and Spontaneous Pulmonary Metastasis , 2005, Clinical & Experimental Metastasis.

[71]  J. Szatkowski,et al.  Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). , 2003, The Journal of bone and joint surgery. American volume.

[72]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[73]  K. Johnson.  An Update. , 1984, Journal of food protection.

[74]  B. Pressman,et al.  Ionophorous antibiotics as models for biological transport. , 1968, Federation proceedings.